Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.

PD1/PD-L1-directed immunotherapy, alone or in combination with chemotherapy, dominates the initial treatment of metastatic non-small cell lung cancer. However, our ability to predict who will benefit from these approaches is limited. In this issue of Cell, Nabet et al. report a novel, blood-based methodology to more accurately predict durable disease control with immunotherapy.